Report for Abhay Tiwari(20Y/M)

Tests asked Monsoon Fever Package - Advanced

Test date 02 Nov 2022 Report status Complete Report

Name : ABHAY TIWARI(20Y/M) ADDRESS :

Ref. By : SELF
A-9/19-19-A1N KAYASTHA TOLA PRAHLAD GHAT
VARANASI UTTAR PRADESH LOCALITY: DAL MANDI
GODAULIYA LANDMARK: CITY: VARANASI

Report Availability Summary

Full Report Available

Note : This is summary page. Please refer to the table below for the details

Test Report Status

● MONSOON FEVER PACKAGE - ADVANCED Available

  C-REACTIVE PROTEIN (CRP) Available

  DENGUE NS1 ANTIGEN - ELISA Available

  DENGUE-IGG - ELISA Available

  DENGUE-IGM - ELISA Available

  ERYTHROCYTE SEDIMENTATION RATE (ESR) Available

  HEMOGRAM - 6 PART (DIFF) Available

  MALARIAL ANTIGEN Available

  TYPHOID-IGG Available

  TYPHOID-IGM Available

Note : Underlined values are Critical Values, Clinician's attention required. Clinically Tested by : Thyrocare Technologies Ltd.
 NAME : ABHAY TIWARI(20Y/M) HOME COLLECTION :
REF. BY : SELF A-9/19-19-A1N KAYASTHA TOLA PRAHLAD GHAT
VARANASI UTTAR PRADESH LOCALITY: DAL
TEST ASKED : MONSOON FEVER PACKAGE - ADVANCED MANDI GODAULIYA LANDMARK: CITY: VARANASI

TEST NAME TECHNOLOGY VALUE UNITS

DENGUE-IGG - ELISA E.L.I.S.A 5.17 Ab units

Reference Range :

Negative : < 9
Equivocal: 9 - 11
Positive : > 11

Clinical Significance
The clinical diagnosis must be interpreted with clinical signs and symptoms of the patient. The results should be
considered in association with other clinical data and patient symptoms. Serological cross-reactivity across the Flavivirus
group is common (ie between St. Louis encephalitis, Murray Valley encephalitis, Japanese encephalitis, West Nile and
yellow fever viruses). These diseases must be excluded before confirmation of diagnosis.

Specifications:
Sensitivity: 98.66% & Specificity:99.93%

Reference:
Pinherio FP, Corber SJ : Global situation of dengue haemorrhagic fever and its emergence in the American.World Health
Stat! 50(3/4):161-169, 1997.
Method : SOLID PHASE CAPTURE ENZYME IMMUNOASSAY

DENGUE-IGM - ELISA E.L.I.S.A 5.32 Ab Units

Reference Range :

Negative : < 9
Equivocal: 9 - 11
Positive : > 11

Clinical Significance
Diagnosis of an infectious disease should not be established on the basis of a single test result. A precise diagnosis
should take into consideration clinical history, symptomatology as well as serological data. The Flaviviridae family includes
the serotypes of Dengue virus as well as yellow fever and Japanese encephalitis viruses. There is a cross reactivity
among flaviviruses, due to the presence of common antigenic determinants.

Reference: Pinheiro FP, CorberSJ : Global situation of Dengue and Dengue haemorrhagic fever and its emergence in the
Americas. World Health Stat ! 50(3/4):161-169, 1997
Method : SOLID PHASE CAPTURE ENZYME IMMUNOASSAY

Please correlate with clinical conditions.

Sample Collected on (SCT) : 02 Nov 2022 05:57

Sample Received on (SRT) : 03 Nov 2022 03:12
Report Released on (RRT) : 03 Nov 2022 07:58

Sample Type : SERUM

Labcode : 0211043107/DG871 Dr Rimi Pandey DNB(Path)
Barcode : AC235918
Page : 1 of 7
Note:- Underlined values are Critical Values, Clinician's attention required. Clinically Tested by :Thyrocare Technologies Ltd
 NAME : ABHAY TIWARI(20Y/M) HOME COLLECTION :
REF. BY : SELF A-9/19-19-A1N KAYASTHA TOLA PRAHLAD GHAT
VARANASI UTTAR PRADESH LOCALITY: DAL MANDI
TEST ASKED : MONSOON FEVER PACKAGE - ADVANCED GODAULIYA LANDMARK: CITY: VARANASI

TEST NAME TECHNOLOGY VALUE UNITS

DENGUE NS1 ANTIGEN - ELISA E.L.I.S.A 2.85 Ag Units
Reference Range :-

Negative : < 9
Equivocal : 9 - 11
Positive : > 11

Clinical Significance:
The detection of highly specific dengue NS1 antigen is possible in the serum of dengue virus infected individuals from the onset of
clinical symptoms in primary as well as secondary infections. Therefore this antigen detection is an important tool for diagnosis of
acute dengue virus infection. It allows rapid detection on the first day of fever, before antibodies appear some 5 or more days late.

Specifications:
Sensitivity: 99.5% & Specificity:100%

Kit Validation Reference:

Gubler DJ Trent DW: Emergence of epidemic dengue/dengue haemorrhage fever as a public health problem in the Americans Infect
Agents Dis 2:383-393, 1993

Please correlate with clinical conditions.

Method:- SOLID PHASE ENZYME IMMUNOASSAY

Sample Collected on (SCT) : 02 Nov 2022 05:57

Sample Received on (SRT) : 03 Nov 2022 03:12
Report Released on (RRT) : 03 Nov 2022 07:58

Sample Type : SERUM

Labcode : 0211043107/DG871 Dr Rimi Pandey DNB(Path)

Barcode : AC235918 Page : 2 of 7

Note:- Underlined values are Critical Values, Clinician's attention required. Clinically Tested by :Thyrocare Technologies Ltd
 NAME : ABHAY TIWARI(20Y/M) HOME COLLECTION :
REF. BY : SELF A-9/19-19-A1N KAYASTHA TOLA PRAHLAD GHAT
VARANASI UTTAR PRADESH LOCALITY: DAL MANDI
TEST ASKED : MONSOON FEVER PACKAGE - ADVANCED GODAULIYA LANDMARK: CITY: VARANASI

TEST NAME TECHNOLOGY VALUE UNITS

C-REACTIVE PROTEIN (CRP) IMMUNOTURBIDIMETRY 1.94 mg/L
Reference Range :-

Acute phase determination : < 5 mg/L

Clinical Significance:

It’s a protein present in the sera of acutely ill patients that bound cell wall C-polysaccharide of streptococcus pneumoniae and
agglutinates the organisms. CRP is one of the strongest acute -phase reactants, with plasma concentrations rising up after myocardial
infarction, stress, trauma, infection, inflammation, surgery, or neoplastic proliferation. Concentrations > 5 to 10 mg/L suggest the
presence of an infection or inflammatory process. Concentrations are generally higher in bacterial than viral infection. The increase in
peak is proportional to tissue damage. Determination of CRP is clinically useful to screen activity of inflammatory diseases such as
rheumatoid arthritis; SLE;Leukemia;after surgery;to detect rejection in renal allograft recipients; to detect neonatal septicemia and
meningitis. However, it is a nonspecific marker and cannot be interpreted without other clinical information.

Specification:

Precision %CV :- 5.0 %CV, Sensitivity :- 0.02-0.20 per 10g/l of CRP

Kit Validation Reference:

Tietz Textbook of clinical chemistry and molecular diagnosis fifth edition chapter 21 P538-539

Please correlate with clinical conditions.

Method:- FULLY AUTOMATED LATEX AGGLUTINATION – BECKMAN COULTER

Sample Collected on (SCT) : 02 Nov 2022 05:57

Sample Received on (SRT) : 03 Nov 2022 03:12
Report Released on (RRT) : 03 Nov 2022 07:58

Sample Type : SERUM

Labcode : 0211043107/DG871 Dr Rimi Pandey DNB(Path)

Barcode : AC235918 Page : 3 of 7

Note:- Underlined values are Critical Values, Clinician's attention required. Clinically Tested by :Thyrocare Technologies Ltd
 NAME : ABHAY TIWARI(20Y/M) HOME COLLECTION :
REF. BY : SELF A-9/19-19-A1N KAYASTHA TOLA PRAHLAD GHAT
VARANASI UTTAR PRADESH LOCALITY: DAL
TEST ASKED : MONSOON FEVER PACKAGE - ADVANCED MANDI GODAULIYA LANDMARK: CITY: VARANASI

TEST NAME TECHNOLOGY RESULT

TYPHOID-IGG IMMUNOASSAY NEGATIVE

Method : LATERAL FLOW IMMUNOASSAY

TYPHOID-IGM IMMUNOASSAY NEGATIVE

Method : LATERAL FLOW IMMUNOASSAY

Note : This is a screening test and a positive report does not confirm diagnosis. All positive cases should be verified by
confirmatory methods
Please correlate with clinical conditions.

Sample Collected on (SCT) : 02 Nov 2022 05:57

Sample Received on (SRT) : 03 Nov 2022 03:12
Report Released on (RRT) : 03 Nov 2022 07:58

Sample Type : SERUM

Labcode : 0211043107/DG871 Dr Rimi Pandey DNB(Path)
Barcode : AC235918
Page : 4 of 7
Note:- Underlined values are Critical Values, Clinician's attention required. Clinically Tested by :Thyrocare Technologies Ltd
 NAME : ABHAY TIWARI(20Y/M) HOME COLLECTION :
REF. BY : SELF A-9/19-19-A1N KAYASTHA TOLA PRAHLAD GHAT
VARANASI UTTAR PRADESH LOCALITY: DAL MANDI
TEST ASKED : MONSOON FEVER PACKAGE - ADVANCED GODAULIYA LANDMARK: CITY: VARANASI

TEST NAME TECHNOLOGY VALUE UNITS

ERYTHROCYTE SEDIMENTATION RATE (ESR) WESTERGREN 15 mm / hr
Reference Range :-

Male : 0-15
Female : 0-20

Please correlate with clinical conditions.

Method:- WESTERGREN

Sample Collected on (SCT) : 02 Nov 2022 05:57

Sample Received on (SRT) : 03 Nov 2022 01:58
Report Released on (RRT) : 03 Nov 2022 05:48

Sample Type : EDTA

Labcode : 0211042963/DG871 Dr Rimi Pandey DNB(Path)

Barcode : AG643412 Page : 5 of 7

Note:- Underlined values are Critical Values, Clinician's attention required. Clinically Tested by :Thyrocare Technologies Ltd
 NAME : ABHAY TIWARI(20Y/M) HOME COLLECTION :
REF. BY : SELF A-9/19-19-A1N KAYASTHA TOLA PRAHLAD GHAT
VARANASI UTTAR PRADESH LOCALITY: DAL
TEST ASKED : MONSOON FEVER PACKAGE - ADVANCED MANDI GODAULIYA LANDMARK: CITY: VARANASI

TEST NAME TECHNOLOGY RESULT

PLASMODIUM FALCIPARUM IMMUNOASSAY NEGATIVE

Method : RAPID IMMUNOASSAY

PLASMODIUM VIVAX IMMUNOASSAY NEGATIVE

Method : RAPID IMMUNOASSAY

Note : This is a screening test and a positive report does not confirm diagnosis. All positive cases should be verified by
confirmatory methods
Please correlate with clinical conditions.

Sample Collected on (SCT) : 02 Nov 2022 05:57

Sample Received on (SRT) : 03 Nov 2022 01:58
Report Released on (RRT) : 03 Nov 2022 05:48

Sample Type : EDTA

Labcode : 0211042963/DG871 Dr Rimi Pandey DNB(Path)
Barcode : AG643412
Page : 6 of 7
Note:- Underlined values are Critical Values, Clinician's attention required. Clinically Tested by :Thyrocare Technologies Ltd
 NAME : ABHAY TIWARI(20Y/M) HOME COLLECTION :
REF. BY : SELF A-9/19-19-A1N KAYASTHA TOLA PRAHLAD GHAT
VARANASI UTTAR PRADESH LOCALITY: DAL
TEST ASKED : MONSOON FEVER PACKAGE - ADVANCED
MANDI GODAULIYA LANDMARK: CITY: VARANASI

TEST NAME VALUE UNITS REFERENCE RANGE

TOTAL LEUCOCYTES COUNT (WBC) 5.34 X 10³ / µL 4.0-10.0
NEUTROPHILS 54.4 % 40-80
LYMPHOCYTE PERCENTAGE 32.6 % 20-40
MONOCYTES 3.4 % 0-10
EOSINOPHILS 9 % 0.0-6.0
BASOPHILS 0.3 % <2
IMMATURE GRANULOCYTE PERCENTAGE(IG%) 0.3 % 0-0.5
NEUTROPHILS - ABSOLUTE COUNT 2.9 X 10³ / µL 2.0-7.0
LYMPHOCYTES - ABSOLUTE COUNT 1.74 X 10³ / µL 1.0-3.0
MONOCYTES - ABSOLUTE COUNT 0.18 X 10³ / µL 0.2-1
BASOPHILS - ABSOLUTE COUNT 0.02 X 10³ / µL 0-0.1
EOSINOPHILS - ABSOLUTE COUNT 0.48 X 10³ / µL 0-0.5
IMMATURE GRANULOCYTES(IG) 0.02 X 10³ / µL 0-0.3
TOTAL RBC 4.93 X 10^6/µL 4.5-5.5
NUCLEATED RED BLOOD CELLS Nil X 10³ / µL <0.01
NUCLEATED RED BLOOD CELLS % Nil % <0.01
HEMOGLOBIN 13.6 g/dL 13-17
HEMATOCRIT(PCV) 44.6 % 40-50
MEAN CORPUSCULAR VOLUME(MCV) 90.5 fL 83-101
MEAN CORPUSCULAR HEMOGLOBIN(MCH) 27.6 pq 27-32
MEAN CORP.HEMO.CONC(MCHC) 30.5 g/dL 31.5-34.5
RED CELL DISTRIBUTION WIDTH - SD(RDW-SD) 47.5 fL 39-46
RED CELL DISTRIBUTION WIDTH (RDW-CV) 14.6 % 11.6-14
PLATELET DISTRIBUTION WIDTH(PDW) 19.3 fL 9.6-15.2
MEAN PLATELET VOLUME(MPV) 13.5 fL 6.5-12
PLATELET COUNT 144 X 10³ / µL 150-400
PLATELET TO LARGE CELL RATIO(PLCR) 52.6 % 19.7-42.4
PLATELETCRIT(PCT) 0.19 % 0.19-0.39
Remarks : Alert!!! Predominantly normocytic normochromic with ovalocytes. Platelets: Appear mildly reduced in smear.

Please Correlate with clinical conditions.

Method : Fully automated bidirectional analyser (6 Part Differential SYSMEX XN-1000)
(This device performs hematology analyses according to the Hydrodynamic Focussing (DC method), Flow
Cytometry Method (using a semiconductor laser), and SLS- hemoglobin method)

~~ End of report ~~

Sample Collected on (SCT) : 02 Nov 2022 05:57

Sample Received on (SRT) : 03 Nov 2022 01:58
Report Released on (RRT) : 03 Nov 2022 05:48
Sample Type : EDTA
Labcode : 0211042963/DG871 Dr Rimi Pandey DNB(Path)
Barcode : AG643412 Page : 7 of 7

Note:- Underlined values are Critical Values, Clinician's attention required. Clinically Tested by :Thyrocare Technologies Ltd